Dublin, Ireland, June 4, 2013 – Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.
...read more
